NAME: 
AIDS-Placebo Clinical Trials Group Study 320 Data (actg320.dat)

SIZE: 
1151 Observations, 16 Variables

SOURCE: 
AIDS Clinical Trials Group 

REFERENCE:
Hosmer, D.W. and Lemeshow, S. and May, S. (2008) 
Applied Survival Analysis: Regression Modeling of Time to Event Data: 
Second Edition, John Wiley and Sons Inc., New York, NY

DESCRITPTIVE ABSTRACT:
The data come from a double-blind, placebo-controlled trial that compared the 
three-drug regimen of indinavir (IDV), open label zidovudine (ZDV) or 
stavudine (d4T) and lamivudine (3TC) with the two-drug regimen of 
zidovudine or stavudine and lamivudine in HIV-infected patients (Hammer 
et al., 1997).  Patients were eligible for the trial if they had no more 
than 200 CD4 cells per cubic millimeter and at least three months of 
prior zidovudine therapy.  Randomization was stratified by CD4 cell 
count at the time of screening.  The  primary  outcome  measure  was  
time  to  AIDS  defining event or death.  Because efficacy results met a 
pre-specified level of significance at an interim analysis, the trial 
was stopped early.

DISCLAIMER:  
This data is also available at the following Wiley's FTP site: 
ftp//ftp.wiley.com/public/sci_tech_med/survival

LIST OF VARIABLES: 

Variable	Name		  Description				    Codes/Values
***************************************************************************************************************************
1		id		  Identification Code			    1-1156
2		time		  Time to AIDS diagnosis or death           Days
3		censor		  Event indicator for AIDS defining	    1 = AIDS defining diagnosis or death
				    diagnosis or death			    0 = Otherwise
4		time_d		  Time to death				    Days
5		censor_d	  Event indicator for death (only)	    1 = Death
		                                                            0 = Otherwise
6		tx		  Treatment indicator			    1 = Treatment includes IDV
									    0 = Control group (treatment regime without IDV)
7		txgrp		  Treatment group indicator		    1 = ZDV + 3TC
									    2 = ZDV + 3TC + IDV
									    3 = d4T + 3TC 
									    4 = d4T + 3TC + IDV
8		strat2		  CD4 stratum at screening		    0 = CD4 <= 50
									    1 = CD4 > 50
9		sex		  Sex					    1 = Male
                                                                            2 = Female 
10		raceth		  Race/Ethnicity			    1 = White Non-Hispanic
									    2 = Black Non-Hispanic
									    3 = Hispanic (regardless of race)
									    4 = Asian, Pacific Islander	
									    5 = American Indian, Alaskan Native
									    6 = Other/unknown
11		ivdrug		  IV drug use history			    1 = Never
									    2 = Currently
									    3 = Previously
12		hemophil	  Hemophiliac				    1 = Yes
                                                                            0 = No
13		karnof		  Karnofsky Performance Scale		    100 = Normal;no complaint
										  no evidence of disease
  									    90 = Normal activity possible; minor
										  signs/symptoms of disease
 								 	    80 = Normal activity with effort;
										  some signs/symptoms of disease
 								 	    70 = Cares for self; normal activity/
										  active work not possible
14		cd4		  Baseline CD4 count			          Cells/milliliter
				  (derived from multiple measurements)
15		priorzdv	  Months of prior ZDV use		    Months
16		age		  Age at Enrollment			    Years